GlassScriptPhysician profile
Sandia Iskandar
NPI 1184986614
$2,436.30
in general payments reported to CMS, 2019-2025
21 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $91.79 · 2021: $224 · 2022: $321 · 2023: $497 · 2024: $608 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.65 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $372.00 | 2020-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.98 | 2023-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $206.13 | 2020-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $200.28 | 2021-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $191.48 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.43 | 2021-2025 | |
| Amgen INC. | $140.50 | 2022-2023 | Tavneos |
| Calliditas Therapeutics US INC. | $133.99 | 2022-2025 | Tarpeyo |
| Scpharmaceuticals INC. | $123.30 | 2023-2025 | |
| Vifor Pharma, INC. | $111.01 | 2020-2025 | Veltassa |
| Ani Pharmaceuticals, INC. | $95.75 | 2022-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $93.92 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $89.65 | 2024-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $87.62 | 2022-2025 | Benlysta |
| Ardelyx, INC. | $44.10 | 2025 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $34.06 | 2024 | Ultomiris |
| Akebia Therapeutics INC | $28.31 | 2025 | Vafseo |
| Lilly USA, LLC | $21.15 | 2025 | Jardiance |
| Nxstage Medical, INC. | $16.28 | 2024 | |
| Kyowa Kirin, INC. | $14.23 | 2024 | Crysvita |
| Baxter Healthcare | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandia Iskandar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.